Credit: Jazz Pharmaceuticals Zanidatamab is a bispecific antibody that binds to 2 non-overlapping extracellular epitopes of the HER2 receptor. Findings showed the ORR was 52% (95% CI, 39-65), of which ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has today approved Ziihera (zanidatamab) for use in adults to treat biliary tract cancer (cancer of the structures that store and ...

Zanidatamab is used when the cancer cannot be removed by surgery and has spread to nearby tissues or other parts of the body. The Medicines and ...

Dr. Shaun P. McKenzie discusses bile duct cancer challenges and why awareness and specialized care help patients get ...

ctDNA is a valuable prognostic biomarker for relapse in early-stage BTC, outperforming carbohydrate antigen 19-9 levels. ctDNA monitoring can detect molecular recurrence earlier than standard ...

At its April 2025 meeting, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) gave a conditional marketing authorization for Ziihera (zanidatamab, Jazz ...

The FDA on Wednesday granted accelerated approval to zanidatamab (Ziihera), a bispecific antibody, for pretreated HER2-positive biliary tract cancer. Approval stipulates use in unresectable or ...

UK MHRA approves Jazz Pharmaceuticals’ zanidatamab for the treatment of biliary tract cancer: United Kingdom Friday, February 20, 2026, 15:00 Hrs [IST] The Medicines and Healthc ...

Compass Therapeutics' tovecimig shows promise in biliary tract cancer with a 17.1% response rate, but further survival data is crucial for potential approval. CMPX's cash runway extends into early ...

Nova Scotia will be the first site in the world to test a potentially groundbreaking cancer treatment. Global pharmaceutical ...

JCO Precision Oncology Conversations features discussions with leading authors of JCO Precision Oncology articles, hosted by Dr. Abdul Rafeh Naqash. Join our experts in engaging conversations as they ...

Zanidatamab-hrii received FDA accelerated approval for HER2-positive biliary tract cancer, showing a 52% objective response rate in the HERIZON-BTC-01 trial. Biliary tract cancers represent 3% of ...